NICE declines 'personalized' Xalkori for lung cancer
This article was originally published in Scrip
Executive Summary
NICE, the HTA body for England and Wales, is not recommending the use of Pfizer's Xalkori (crizotinib) for lung cancer under the UK's NHS in new draft guidance.